Chaminda Salgado is a CMC Innovation Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), where he leads several innovative manufacturing projects, as well as the Analytical Innovation Call for Proposals, aligned with CEPIs 100 day mission to disrupt the next potential pandemic. Chaminda also contributes to the ATMP working group at The British Pharmacopoeia, providing guidance to cell and gene therapy developers.

Previously, Chaminda started his career at the Chemical & Biological Defence facility at Porton Down UK. He then transitioned into Pharma (initially at GSK) with CMC project accountability from candidate to FTIH, and with CGT from clinic to launch. He was part of the GSK leadership team that commercialised Strimvellis, the first gene modified cell therapy for children.

With over two decades of experience, Chaminda has contributed to advancing the field of large molecule CMC through innovative strategies and a deep understanding of the quality and regulatory landscape.